Association between benign and malignant peripheral nerve sheath tumors in NF1
Abstract
Objective: People with neurofibromatosis type 1 (NF1) have a 10% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST). MPNSTs are often metastatic and are a frequent cause of death among people with NF1. Clinical evidence suggests that most MPNSTs in people with NF1 develop from preexisting plexiform neurofibromas. However, it is not known whether an individual's risk of developing an MPNST is associated with the burden of benign neurofibromas. The authors conducted a study to determine whether people with NF1 who have benign neurofibromas of various kinds are at greater risk of developing MPNSTs than patients with NF1 who lack these benign tumors.
Methods: Clinical information on 476 NF1 probands in the Henri Mondor Database was analyzed by logistic regression to examine associations between MPNSTs and internal plexiform, superficial plexiform, subcutaneous, and cutaneous neurofibromas.
Results: Individuals with subcutaneous neurofibromas were approximately three times more likely to have internal plexiform neurofibromas or MPNSTs than individuals without subcutaneous neurofibromas. Individuals with internal plexiform neurofibromas were 20 times more likely to have MPNSTs than individuals without internal plexiform neurofibromas. When this analysis was done with both subcutaneous and internal plexiform neurofibromas as explanatory variables, only the association of MPNSTs with internal plexiform neurofibromas remained significant.
Conclusions: The observation that malignant peripheral nerve sheath tumors are strongly associated with internal plexiform neurofibromas suggests that patients with neurofibromatosis type 1 with these benign tumors warrant increased surveillance for malignancy.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68:1110–1118.
2.
Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol 1995;75:136–140.
3.
Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006–2021.
4.
Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62:1573–1577.
5.
Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311–314.
6.
De Raedt T, Brems H, Wolkenstein P, Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003;72:1288–1292.
7.
Loree TR, North Jr, JH Werness BA, Nangia R, Mullins AP, Hicks Jr. WL Malignant peripheral nerve sheath tumors of the head and neck: analysis of prognostic factors. Otolaryngol Head Neck Surg 2000;122:667–672.
8.
Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet 1999;89:23–30.
9.
Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000;5:477–485.
10.
King AA, Debaun MR, Riccardi VM, Gutmann DH. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000;93:388–392.
11.
Huson SM. Neurofibromatosis 1: a clinical and genetic overview. In: Huson SM, Hughes RAC, eds. The neurofibromatoses: a pathogenetic and clinical overview. London: Chapman and Hall Medical, 1994:160–203.
12.
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575–578.
13.
Gutmann DH, Aylsworth A, Carey JC, The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51–57.
14.
Friedman JM, Riccardi VM. Clinical and epidemiological features. In: Gutmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: phenotype, natural history, and pathogenesis. 3rd ed. Baltimore: John Hopkins University Press, 1999:26–86.
15.
Friedman JM, Birch P, Greene C. National Neurofibromatosis Foundation International Database. Am J Med Genet 1993;45:88–91.
16.
Daschner K, Assum G, Eisenbarth I, Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene. Biochem Biophys Res Commun 1997;234:346–350.
17.
Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995;11:90–92.
18.
Kluwe L, Friedrich R, Mautner VF. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 1999;24:283–285.
19.
Kluwe L, Friedrich RE, Mautner VF. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet Cytogenet 1999;113:65–69.
20.
Rasmussen SA, Overman J, Thomson SA, Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 2000;28:425–431.
21.
Serra E, Puig S, Otero D, Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997;61:512–519.
22.
Serra E, Ars E, Ravella A, Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet 2001;108:416–429.
23.
Skuse GR, Kosciolek BA, Rowley PT. The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin. Am J Hum Genet 1991;49:600–607.
24.
Tucker T, Friedman JM. Pathogenesis of hereditary tumors: beyond the “two-hit” hypothesis. Clin Genet 2002;62:345–357.
25.
Szudek J, Birch P, Riccardi VM, Evans DG, Friedman JM. Associations of clinical features in neurofibromatosis 1 (NF1). Genet Epidemiol 2000;19:429–439.
26.
McGaughran JM, Harris DI, Donnai D, A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 1999;36:197–203.
27.
Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988;111:1355–1381.
28.
Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997;70:138–143.
29.
Tonsgard JH, Kwak SM, Short MP, Dachman AH. CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology 1998;50:1788–1760.
30.
Thakkar SD, Feigen U, Mautner VF. Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety. Neuroradiology 1999;41:625–629.
31.
Mautner VF, Friedrich RE, von Deimling A, Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma. Neuroradiology 2003;45:618–625.
32.
Doorn PF. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol 1995;21:78–82.
33.
Khosrotehrani K, Bastuji-Garin S, Riccardi VM, Birch P, Friedman JM, Wolkenstein P. Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: a cohort study of 703 patients. Am J Med Genet 2005;132:49–53.
34.
Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000;151:33–40.
Information & Authors
Information
Published In
Copyright
© 2005.
Publication History
Published online: July 25, 2005
Published in print: July 26, 2005
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- A worldwide bibliometric analysis of malignant peripheral nerve sheath tumors from 2000 to 2022, Frontiers in Oncology, 13, (2023).https://doi.org/10.3389/fonc.2023.1111985
- Assessing the role of sodium fluorescein in peripheral nerve sheath tumors and mimicking lesions surgery: An update after 142 cases, Frontiers in Oncology, 12, (2023).https://doi.org/10.3389/fonc.2022.1070878
- Perinatal folate levels do not influence tumor latency or multiplicity in a model of NF1 associated plexiform-like neurofibromas, BMC Research Notes, 16, 1, (2023).https://doi.org/10.1186/s13104-023-06515-8
- Surgical management of craniospinal axis malignant peripheral nerve sheath tumors: a single-institution experience and literature review, World Journal of Surgical Oncology, 21, 1, (2023).https://doi.org/10.1186/s12957-023-03227-y
- Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1, British Journal of Dermatology, (2023).https://doi.org/10.1093/bjd/ljad390
- Droplet Digital PCR for Fast and Accurate Characterization of NF1 Locus Deletions, The Journal of Molecular Diagnostics, (2023).https://doi.org/10.1016/j.jmoldx.2023.11.005
- Distinct Transcriptional Profiles in the Different Phenotypes of Neurofibroma from the Same Subject with Neurofibromatosis 1, Journal of Investigative Dermatology, (2023).https://doi.org/10.1016/j.jid.2023.03.1688
- Rare case of Malign Peripheral Nerve Sheath Tumor complicating a solitary giant neurofibroma of the thigh, International Journal of Surgery Case Reports, 106, (108224), (2023).https://doi.org/10.1016/j.ijscr.2023.108224
- Pitfalls in correct diagnosis and treatment of Soft Tissue Sarcoma of the foot and ankle – A report of two challenging cases, Fuß & Sprunggelenk, 21, 1, (55-69), (2023).https://doi.org/10.1016/j.fuspru.2023.02.004
- Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment, Skeletal Radiology, (2023).https://doi.org/10.1007/s00256-023-04497-z
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.